Mammoth Biosciences disclosed first monkey data for its lead in vivo gene editing program aimed at permanently lowering triglycerides, and announced plans for an initial clinical trial. The preclinical results indicate on‑target editing in liver tissue and triglyceride reductions in nonhuman primates, supporting a first‑in‑human study prospect. Mammoth’s program leverages CRISPR‑adjacent editing tools and marks the company’s push from diagnostics and enzyme engineering into therapeutic editing. The move follows increased investor and scientific attention on one‑time gene‑editing medicines for cardiometabolic risk reduction.